ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

Company Overview

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S. Food and Drug Administration approval for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Beyond NUPLAZID, ACADIA is pursuing additional indications for pimavanserin in dementia-related psychosis and Alzheimer’s disease psychosis, as well as exploring novel candidates for schizophrenia and other neuropsychiatric disorders. These efforts are complemented by strategic collaborations, translational research initiatives, and robust clinical trial programs to expand the company’s impact on patient care.

ACADIA serves patients and healthcare providers primarily in North America, with ongoing clinical studies and regulatory submissions extending into Europe and Asia-Pacific regions. The company leverages partnerships with academic institutions and industry collaborators to accelerate development timelines and enhance its global footprint. Guided by a leadership team with extensive experience in CNS drug development, ACADIA continues to build on its scientific heritage and commitment to delivering differentiated therapies for complex neurological conditions.

Key Stats

• Today's Range: $25.35 to $26.44
• 50-Day Range: $20.89 to $26.55
• 52-Week Range: $19.69 to $28.35
• Volume: 1.53 million shs
• Average Volume: 1.34 million shs
• Market Capitalization: $4.43 billion
• P/E Ratio: 11.76
• Dividend Yield: N/A
• Price Target: $32.31
• Consensus Rating: Moderate Buy

ACADIA Pharmaceuticals Stock Analysis - MarketRank™

ACADIA Pharmaceuticals scored higher than 90% of companies evaluated by MarketBeat, and ranked 54th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 13 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

ACADIA Pharmaceuticals has a consensus price target of $32.31, representing about 24.9% upside from its current price of $25.87.

Amount of Analyst Coverage

ACADIA Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 146.15%

Earnings Growth

Earnings for ACADIA Pharmaceuticals are expected to grow by 146.15% in the coming year, from $0.39 to $0.96 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ACADIA Pharmaceuticals is 11.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of ACADIA Pharmaceuticals is 11.76, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 280.88.

Price to Earnings Growth Ratio

ACADIA Pharmaceuticals has a PEG Ratio of 18.41. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

ACADIA Pharmaceuticals has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.73% of the float of ACADIA Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 7.61.

Change versus previous month

Short interest in ACADIA Pharmaceuticals has recently increased by 0.72%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ACADIA Pharmaceuticals does not currently pay a dividend.

Dividend Growth

ACADIA Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.12

News Sentiment

ACADIA Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for ACADIA Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

Only 6 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $652,474.00 in company stock.

Percentage Held by Insiders

26.20% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 7/31/2026
• Next Earnings (Confirmed): 8/04/2026
• Canaccord Genuity's 46th Annual Growth Conference: 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACAD
• CIK: 1070494
• Web: www.acadia-pharm.com
• Phone: (858) 558-2871
• Fax: 858-558-2872
• Employees: 510
• Year Founded: 1993

Price Target and Rating

• Average Price Target for ACADIA Pharmaceuticals: $32.31
• High Price Target: $40.00
• Low Price Target: $14.50
• Potential Upside/Downside: +24.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.20
• Trailing P/E Ratio: 11.76
• Forward P/E Ratio: 66.33
• P/E Growth: 18.41
• Net Income: $391 million
• Net Margins: 34.30%
• Pretax Margin: 10.51%
• Return on Equity: 9.61%
• Return on Assets: 7.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.59
• Quick Ratio: 3.48

Sales & Book Value

• Annual Sales: $1.07 billion
• Price / Sales: 4.13
• Cash Flow: $0.86 per share
• Price / Cash Flow: 29.93
• Book Value: $7.25 per share
• Price / Book: 3.57

Miscellaneous

• Outstanding Shares: 171,240,000
• Free Float: 126,372,000
• Market Cap: $4.43 billion
• Optionable: Optionable
• Beta: 0.80